Last reviewed 2026-05-30 · How we verify

Dipeptide Alanyl-Glutamine

Medical Center Alkmaar · Phase 1 active Small molecule ✓ Verified May 2026

Dipeptide Alanyl-Glutamine is a Small molecule drug developed by Medical Center Alkmaar. It is currently in Phase 1 development.

Dipeptide Alanyl-Glutamine is a small molecule with the chemical name Alanyl-Glutamine, also known as Alanyl Glutamine or Alanyl-GLUTAMINE DIPEPTIDE. It has been studied in clinical trials for various conditions, including critical illness, trauma, pressure ulcers, and cardiac conditions such as aortic valve stenosis and insufficiency.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Dipeptide Alanyl-Glutamine
Sponsor	Medical Center Alkmaar
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dipeptide Alanyl-Glutamine CI brief — competitive landscape report
Dipeptide Alanyl-Glutamine updates RSS · CI watch RSS
Medical Center Alkmaar portfolio CI

Frequently asked questions about Dipeptide Alanyl-Glutamine

What is Dipeptide Alanyl-Glutamine?

Dipeptide Alanyl-Glutamine is a Small molecule drug developed by Medical Center Alkmaar.

Who makes Dipeptide Alanyl-Glutamine?

Dipeptide Alanyl-Glutamine is developed by Medical Center Alkmaar (see full Medical Center Alkmaar pipeline at /company/medical-center-alkmaar).

What development phase is Dipeptide Alanyl-Glutamine in?

Dipeptide Alanyl-Glutamine is in Phase 1.

Manufacturer: Medical Center Alkmaar — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing